Harish Kumar, Suman Mazumder, Neeraj Sharma, Sayak Chakravarti, Mark D Long, Nathalie Meurice, Joachim Petit, Song Liu, Marta Chesi, Sabyasachi Sanyal, A Keith Stewart, Shaji Kumar, Leif Bergsagel, S Vincent Rajkumar, Linda B Baughn, Brian G Van Ness, Amit Kumar Mitra
Multiple myeloma (MM) is an incurable plasma cell malignancy with dose-limiting toxicities and inter-individual variation in response/resistance to the standard-of-care/primary drugs, proteasome inhibitors (PIs), and immunomodulatory derivatives (IMiDs). Although newer therapeutic options are potentially highly efficacious, their costs outweigh the effectiveness. Previously, we have established that clofazimine (CLF) activates peroxisome proliferator-activated receptor-γ, synergizes with primary therapies, and targets cancer stem-like cells (CSCs) in drug-resistant chronic myeloid leukemia (CML) patients...
2022: Frontiers in Oncology